NCT03622047

Brief Summary

The participants: 1800 full-term primiparas will be selected with ASA I-Ⅱgrade, 20 to 35 years old and weighing 55 to 90 kg in the investigator's hospital from may 2018 to December 2018. 1200 primiparas were divided into A and B according to the computer randomized numbers, and 600 parturients without labor analgesia in the same period were selected as group C, with 600 patients in each group. All parturients signed the informed consent form and were approved by the hospital ethics Committee.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,800

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 9, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 9, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

August 15, 2018

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2020

Completed
Last Updated

February 5, 2020

Status Verified

February 1, 2020

Enrollment Period

2 years

First QC Date

July 9, 2018

Last Update Submit

February 3, 2020

Conditions

Keywords

Labor, Analgesia, Dexmedetomidine, Sufentanil

Outcome Measures

Primary Outcomes (1)

  • The onset time

    A drug's effects to come to prominence upon administration.

    30 minutes

Secondary Outcomes (1)

  • analgesic effect

    1 day

Study Arms (3)

dexmedetomidine ropivacaine

EXPERIMENTAL

Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.

Drug: Dexmedetomidine ropivacaineDrug: No analgesia labor

sufentanil ropivacaine

EXPERIMENTAL

compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.

Drug: Dexmedetomidine ropivacaineDrug: No analgesia labor

No analgesia labor

EXPERIMENTAL

Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.

Drug: Dexmedetomidine ropivacaineDrug: No analgesia labor

Interventions

Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.

Also known as: sufentanil ropivacaine
No analgesia labordexmedetomidine ropivacainesufentanil ropivacaine

No analgesia labor control group

Also known as: No analgesia labor control
No analgesia labordexmedetomidine ropivacainesufentanil ropivacaine

Eligibility Criteria

Age22 Years - 42 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ASA I-Ⅱ, aged 22 - 42,
  • gestational age ≥ 37, weight 55 - 90 kg,
  • labor analgesia is required by full-term primiparas.

You may not qualify if:

  • serious cardiovascular and cerebrovascular system diseases,
  • bradycardia, conduction block
  • fetal distress
  • contraindications of intraspinal anesthesia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

International Peace Maternity and Child Hospital

Shanghai, Shanghai Municipality, 200030, China

RECRUITING

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Yongtao Gao, MD

    Shanghai Jiao Tong University School of Medicine

    STUDY DIRECTOR

Central Study Contacts

zeyong yang, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of Anesthesiology, Principal Investigator, Clinical Professor,International Peace Maternity and Child Hospital

Study Record Dates

First Submitted

July 9, 2018

First Posted

August 9, 2018

Study Start

August 15, 2018

Primary Completion

August 1, 2020

Study Completion

August 1, 2020

Last Updated

February 5, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations